Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
2.

Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals.

Brugulat-Serrat A, Salvadó G, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Brain Imaging Behav. 2019 Jul 5. doi: 10.1007/s11682-019-00151-2. [Epub ahead of print]

PMID:
31278650
3.

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.

Morenas-Rodríguez E, Alcolea D, Suárez-Calvet M, Muñoz-Llahuna L, Vilaplana E, Sala I, Subirana A, Querol-Vilaseca M, Carmona-Iragui M, Illán-Gala I, Ribosa-Nogué R, Blesa R, Haass C, Fortea J, Lleó A.

Sci Rep. 2019 May 24;9(1):7803. doi: 10.1038/s41598-019-44173-8.

4.

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019 Apr 1;23:101801. doi: 10.1016/j.nicl.2019.101801. [Epub ahead of print]

5.

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A.

Front Neurol. 2019 Mar 26;10:280. doi: 10.3389/fneur.2019.00280. eCollection 2019.

6.

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.

Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.

7.

The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.

Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M.

Mol Psychiatry. 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]

PMID:
30899092
8.

Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.

Salvadó G, Brugulat-Serrat A, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2019 Jan 24;11(1):12. doi: 10.1186/s13195-018-0460-1.

9.

Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2019 Jan 10;14(1):1. doi: 10.1186/s13024-018-0301-5.

10.

Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort.

Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Minguillon C, Cacciaglia R, Gramunt N, Falcon C; ALFA Study, Gispert JD, Molinuevo JL.

Alzheimers Res Ther. 2018 Dec 20;10(1):123. doi: 10.1186/s13195-018-0449-9.

11.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

12.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

13.

Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline.

Sánchez-Benavides G, Grau-Rivera O, Cacciaglia R, Suárez-Calvet M, Falcon C, Minguillon C, Gramunt N, Sala-Vila A, Gispert JD, Molinuevo JL.

J Alzheimers Dis. 2018;65(1):181-191. doi: 10.3233/JAD-180378.

14.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

15.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, Lladó A, Sánchez-Valle R, Molinuevo JL, García-Ribas G, Compta Y, Martí MJ, Piñol-Ripoll G, Amer-Ferrer G, Noguera A, García-Martín A, Fortea J, Lleó A.

Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.

PMID:
28592456
16.

The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.

Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deußing M, Suárez-Calvet M, Mazaheri F, Parhizkar S, Pettkus N, Wurst W, Feederle R, Bartenstein P, Mueggler T, Arzberger T, Knuesel I, Rominger A, Haass C.

EMBO J. 2017 Jul 3;36(13):1837-1853. doi: 10.15252/embj.201796516. Epub 2017 May 30.

17.

Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis.

Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ, Ozmen L, Suárez-Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C, Rominger A.

Front Aging Neurosci. 2017 Jan 31;9:8. doi: 10.3389/fnagi.2017.00008. eCollection 2017.

18.

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2.

Gispert JD, Monté GC, Suárez-Calvet M, Falcon C, Tucholka A, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement (Amst). 2016 Dec 22;6:50-59. doi: 10.1016/j.dadm.2016.12.002. eCollection 2017.

19.

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.

Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C; Dominantly Inherited Alzheimer Network.

Sci Transl Med. 2016 Dec 14;8(369):369ra178.

20.

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.

Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement. 2016 Dec;12(12):1259-1272. doi: 10.1016/j.jalz.2016.06.005. Epub 2016 Jul 14.

PMID:
27423963
21.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123. Print 2016 May.

22.

Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.

Suárez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H, Edbauer D, Kremmer E, Göbl C, Resch M, Bourgeois B, Madl T, Reber S, Jutzi D, Ruepp MD, Mackenzie IR, Ansorge O, Dormann D, Haass C.

Acta Neuropathol. 2016 Apr;131(4):587-604. doi: 10.1007/s00401-016-1544-2. Epub 2016 Feb 19.

PMID:
26895297
23.

Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion.

Suárez-Calvet M, Camacho V, Gómez-Ansón B, Antón S, Vives-Gilabert Y, Dols-Icardo O, Clarimón J, Alcolea D, Blesa R, Fortea J, Lleó A.

Alzheimer Dis Assoc Disord. 2015 Oct-Dec;29(4):353-6. doi: 10.1097/WAD.0000000000000056. No abstract available.

PMID:
25203513
24.

TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleó A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sánchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C.

Sci Transl Med. 2014 Jul 2;6(243):243ra86. doi: 10.1126/scitranslmed.3009093.

25.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.

J Alzheimers Dis. 2014;42(1):157-67. doi: 10.3233/JAD-140240.

PMID:
24820015
26.

Endothelial progenitor cells in acute ischemic stroke.

Martí-Fàbregas J, Crespo J, Delgado-Mederos R, Martínez-Ramírez S, Peña E, Marín R, Dinia L, Jiménez-Xarrié E, Fernández-Arcos A, Pérez-Pérez J, Querol L, Suárez-Calvet M, Badimon L.

Brain Behav. 2013 Nov;3(6):649-55. doi: 10.1002/brb3.175. Epub 2013 Sep 22.

27.

Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation.

Suárez-Calvet M, Dols-Icardo O, Lladó A, Sánchez-Valle R, Hernández I, Amer G, Antón-Aguirre S, Alcolea D, Fortea J, Ferrer I, van der Zee J, Dillen L, Van Broeckhoven C, Molinuevo JL, Blesa R, Clarimón J, Lleó A.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):684-91. doi: 10.1136/jnnp-2013-305972. Epub 2013 Dec 4.

PMID:
24309270
28.

Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.

Suárez-Calvet M, Belbin O, Pera M, Badiola N, Magrané J, Guardia-Laguarta C, Muñoz L, Colom-Cadena M, Clarimón J, Lleó A.

J Neurochem. 2014 Jan;128(2):330-9. doi: 10.1111/jnc.12466. Epub 2013 Oct 24.

29.

Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.

Dols-Icardo O, García-Redondo A, Rojas-García R, Sánchez-Valle R, Noguera A, Gómez-Tortosa E, Pastor P, Hernández I, Esteban-Pérez J, Suárez-Calvet M, Antón-Aguirre S, Amer G, Ortega-Cubero S, Blesa R, Fortea J, Alcolea D, Capdevila A, Antonell A, Lladó A, Muñoz-Blanco JL, Mora JS, Galán-Dávila L, Rodríguez De Rivera FJ, Lleó A, Clarimón J.

Hum Mol Genet. 2014 Feb 1;23(3):749-54. doi: 10.1093/hmg/ddt460. Epub 2013 Sep 20.

PMID:
24057670
30.

Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease.

Polydoro M, de Calignon A, Suárez-Calvet M, Sanchez L, Kay KR, Nicholls SB, Roe AD, Pitstick R, Carlson GA, Gómez-Isla T, Spires-Jones TL, Hyman BT.

J Neurosci. 2013 Aug 14;33(33):13300-11. doi: 10.1523/JNEUROSCI.0881-13.2013.

31.

Comparison of 2 diagnostic criteria for the behavioral variant of frontotemporal dementia.

Costa S, Suárez-Calvet M, Antón S, Dols-Icardo O, Clarimón J, Alcolea D, Fortea J, Carmona M, Sala I, Sánchez-Saudinós MB, Blesa R, Lleó A.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):469-76. doi: 10.1177/1533317513488918. Epub 2013 May 21.

PMID:
23695224
32.

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease.

Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Suárez-Calvet M, Lladó A, Barrera-Ocampo AA, Sepulveda-Falla D, Blesa R, Molinuevo JL, Clarimón J, Ferrer I, Gelpi E, Lleó A.

Acta Neuropathol. 2013 Feb;125(2):201-13. doi: 10.1007/s00401-012-1062-9. Epub 2012 Dec 6.

33.

Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease.

Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suárez-Calvet M, Lleo A, Lloyd DG, Ma D, Sastre M.

Neurobiol Aging. 2013 Apr;34(4):1105-15. doi: 10.1016/j.neurobiolaging.2012.09.010. Epub 2012 Oct 11.

PMID:
23063647
34.

Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia.

Dols-Icardo O, Suárez-Calvet M, Hernández I, Amer G, Antón-Aguirre S, Alcolea D, Fortea J, Boada M, Tárraga L, Blesa R, Lleó A, Clarimón J.

Neurobiol Aging. 2012 Aug;33(8):1851.e17-9. doi: 10.1016/j.neurobiolaging.2012.03.005. Epub 2012 Apr 11.

PMID:
22502998
35.

Propagation of tau pathology in a model of early Alzheimer's disease.

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT.

Neuron. 2012 Feb 23;73(4):685-97. doi: 10.1016/j.neuron.2011.11.033. Erratum in: Neuron. 2012 Oct 18;76(2):461.

36.

Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy.

Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gonçalves SA, Pera M, Suárez-Calvet M, Clarimon J, Outeiro TF, Lleó A.

PLoS One. 2011;6(10):e26609. doi: 10.1371/journal.pone.0026609. Epub 2011 Oct 24.

37.

Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

Martinez-Ramirez S, Delgado-Mederos R, Marín R, Suárez-Calvet M, Sáinz MP, Alejaldre A, Vidal-Jordana Á, Martí-Vilalta JL, Martí-Fàbregas J.

J Neurol. 2012 Jan;259(1):111-8. doi: 10.1007/s00415-011-6137-3. Epub 2011 Jun 18.

PMID:
21688044
38.

Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes.

Setó-Salvia N, Clarimón J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O, Mateo JI, Regaña D, Martínez-Corral M, Marquié M, Alcolea D, Suárez-Calvet M, Molina-Porcel L, Dols O, Gómez-Isla T, Blesa R, Lleó A, Kulisevsky J.

Arch Neurol. 2011 Mar;68(3):359-64. doi: 10.1001/archneurol.2011.17.

PMID:
21403021
39.

Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

Badiola N, Suárez-Calvet M, Lleó A.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):727-40. Review.

PMID:
20942789
40.

Polyradiculoneuropathy associated to human herpesvirus 2 in an HIV-1-infected patient (Elsberg syndrome): case report and literature review.

Suarez-Calvet M, Rojas-Garcia R, Querol L, Sarmiento LM, Domingo P.

Sex Transm Dis. 2010 Feb;37(2):123-5. doi: 10.1097/OLQ.0b013e3181bcaf7d. Review.

PMID:
19858783
41.

Blood pressure is not associated with haematoma enlargement in acute intracerebral haemorrhage.

Martí-Fàbregas J, Martínez-Ramírez S, Martínez-Corral M, Díaz-Manera J, Querol L, Suárez-Calvet M, de Juan M, Santaló M, Marín R, Martí-Vilalta JL.

Eur J Neurol. 2008 Oct;15(10):1085-90. doi: 10.1111/j.1468-1331.2008.02254.x. Epub 2008 Aug 20.

PMID:
18717722
42.

ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer.

Sabater L, Bataller L, Suárez-Calvet M, Saiz A, Dalmau J, Graus F.

J Neuroimmunol. 2008 Sep 15;201-202:163-5. doi: 10.1016/j.jneuroim.2008.01.018. Epub 2008 Jul 21.

Supplemental Content

Loading ...
Support Center